Sylvie L.
- Country
- Germany
- Department
- Dep. of Hematology and Oncology
Research Overview
- Phase Ib Evaluation of Neoadjuvant Tislelizumab Plus FLOT in Resectable Esophagogastric Adenocarcinoma
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 244 of 504 partner sites.
Specializations
Gastroesophageal Cancer Research
Specializes in investigating novel therapeutic approaches for gastric and gastroesophageal junction adenocarcinoma, with particular emphasis on targeted and immunotherapy treatments.
- Early-stage disease management
- HER2-positive cancer treatments
- Perioperative therapy strategies
Focuses on combining immunotherapy agents with established treatment protocols to improve patient outcomes.
Colorectal Cancer Studies
Leads investigations in metastatic colorectal cancer treatment approaches, particularly focusing on post-resection therapies and innovative drug combinations.
- Post-surgical treatment optimization
- Advanced stage disease management
- Targeted therapy combinations
Explores new therapeutic strategies for both early-stage and advanced colorectal cancer.
Innovative Treatment Approaches
Investigates cutting-edge therapeutic combinations incorporating immunotherapy, targeted therapies, and conventional treatment modalities.
- Novel drug combinations
- Organ preservation strategies
- Multimodal treatment approaches
Specializes in developing personalized treatment strategies based on specific molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.